DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Goldman Sachs - 2 Scott Schoenhaus - 1 Chris Gibson - 1 Jensen Huang - 1 Leerink - 1 Mani Foroohar - 1 Foroohar - 1 Recursion's - 1
Top related locs:
U.S biopharma Biohive
Top related orgs:
Analysts - 1 Capital - 1 Nvidia - 1 ARK Investment Management - 1 REC - 1 CCM - 1 Union - 1 Bayer - 1

Search resuls for: "Salveen Richter"


5 mentions found


☆ Investors want proof AI will aid drug discovery. Evidence may come in the second half
  + stars: | 2024-07-06 | by ( Christina Cheddar Berk | In | ) www.cnbc.com   time to read: +10 min
Analysts who have been following companies on the cutting edge of using generative AI for drug discovery say it is still very early days. But these endorsements haven't lifted Recursion shares out of a slump. RXRX 1Y mountain Recursion shares over the past year. The drug company will be a beta user of Recursion's LOWE (Large Language Model-Orchestrated Workflow Engine) and the pair are also partnering on oncology research. SDGR 1Y mountain Schrodinger shares over the past year.
Persons: Scott Schoenhaus, Chris Gibson, Jensen Huang, Leerink, Mani Foroohar, Foroohar, Recursion's, KeyBanc's Schoenhaus, Needham, Gil Blum, it's, Recursion's LOWE, Blum, Eli Lilly, AbCellera, KeyBanc's, Schoenhaus, FactSet, Allison Bratzel, Piper Sandler, Goldman Sachs, Salveen Richter, Peter Lawson, Lawson, Japan's Takeda, Schrodinger, Leerink's Foroohar Organizations: Analysts, Capital, Nvidia, ARK Investment Management, REC, CCM, Union, Bayer, Therapeutics, Dynamo, RLY, Barclays, Japan's Locations: U.S, biopharma, Biohive
☆ We've only seen the beginning of Moderna's story, says Goldman Sachs' Salveen Richter
  + stars: | 2023-07-11 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWe've only seen the beginning of Moderna's story, says Goldman Sachs' Salveen RichterSalveen Richter, Goldman Sachs lead biotech analyst, joins 'Closing Bell Overtime' to discuss the biotech sector and how investors should play in the space.
Persons: Goldman Sachs, Salveen Richter Salveen Richter
☆ Here's where to look for the next developments in the fight against Alzheimer's disease
  + stars: | 2023-01-17 | by ( Christina Cheddar Berk | ) www.cnbc.com   time to read: +10 min
The Centers for Disease Control and Prevention estimates 5.8 million Americans were living with the disease in 2020 . BIIB 6M mountain Biogen's stock is trading well above its lows Leqembi treats Alzheimer's disease by targeting amyloid-beta plaques in the brain. Attention shifts to Eli Lilly Shares of other Alzheimer's drug developers have often mirrored Biogen's moves. Small drug developers Smaller Alzheimer's drug developers have also been boosted by research developments. Still in an early stage of its research, Prothena has traded as a proxy for developments in Alzheimer's treatment.
☆ A year after hitting a record, here are the biggest Nasdaq-100 winners and losers
  + stars: | 2022-11-20 | by ( Fred Imbert | ) www.cnbc.com   time to read: +3 min
On Nov. 19, 2021, the Nasdaq-100 index — which is made up of the 100-largest Nasdaq Composite stocks — hit a record closing high of 16,573.34. DocuSign and Zoom Video have fallen more than 80% and 67%, respectively, since the Nasdaq-100 reached its record high. Megacap stocks such as Meta Platforms , Tesla and Amazon have also plunged over the past 12 months, in part due to their high valuations. Vertex Pharmaceuticals has rallied 69.5% since the Nasdaq-100 closed at a record. O'Reilly Automotive, T-Mobile and Gilead Sciences are also among the big Nasdaq-100 winners over the year since the Nasdaq closed at an all-time high.
☆ Goldman upgrades Biogen, says it’s poised to address early Alzheimer’s market next year
  + stars: | 2022-10-26 | by ( Tanaya Macheel | ) www.cnbc.com   time to read: +2 min
Biogen shares have a lot more potential upside for investors thanks to positive new data around the company's early Alzheimer's drug, Goldman Sachs said Wednesday. The upgrade followed the company's earnings call, which had a big focus on the drug, lecanemab, an anti-amyloid antibody that is in phase 3 trials. Goldman also raised its revenue estimates for the drug to $14 billion in 2035, compared with prior estimates of $2 billion. "The company is now poised to address the early Alzheimer's disease market in 2023+ following the recent topline lecanemab Ph3 (CLARITY-AD) data," Goldman analyst Salveen Richter said in a note. "With BIIB shares now trading at ~$270 post the topline CLARITY-AD data, there is roughly ~$80/share reflected in the stock for Alzhiemer's disease," Richter said.
0 next >>
Total: 5